Chromosome 8q24.1/c-MYCabnormality: a marker for high-risk myeloma

Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management

(2013) S. Vincent Rajkumar   AMERICAN JOURNAL OF HEMATOLOGY

Cytogenetics of extramedullary manifestations in multiple myeloma

(2013) Lisa Billecke et al.   BRITISH JOURNAL OF HAEMATOLOGY

Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma

(2012) P. L. Bergsagel et al.   BLOOD

Cancer statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

(2012) Pieter Sonneveld et al.   JOURNAL OF CLINICAL ONCOLOGY

Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

(2012) C Fernández de Larrea et al.   LEUKEMIA

Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p

(2011) K. Neben et al.   BLOOD

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2

(2011) N. C. Munshi et al.   BLOOD

Approach to the treatment of multiple myeloma: a clash of philosophies

(2011) S. V. Rajkumar et al.   BLOOD

Shifts in the Therapeutic Paradigm for Patients Newly Diagnosed with Multiple Myeloma: Maintenance Therapy and Overall Survival

(2011) Antonio Palumbo et al.   CLINICAL CANCER RESEARCH

Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment Approach

(2011) Joan Bladé et al.   JOURNAL OF CLINICAL ONCOLOGY

Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance

(2010) B. Nair et al.   BLOOD

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

(2010) Michele Cavo et al.   LANCET

Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features

(2010) Lekidelu Taddesse-Heath et al.   MODERN PATHOLOGY

Frequent upregulation ofMYCin plasma cell leukemia

(2009) Laura Chiecchio et al.   GENES CHROMOSOMES & CANCER

Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case

(2009) L. Chiecchio et al.   HAEMATOLOGICA

Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines

(2009) Shaji K. Kumar et al.   MAYO CLINIC PROCEEDINGS

c-Myc: Linking Transformation and Genomic Instability

(2008) Edward Prochownik   CURRENT MOLECULAR MEDICINE

Apoptotic signaling by c-MYC

(2008) B Hoffman et al.   ONCOGENE